Showing frustration during a state legislative hearing Monday, Senator Mark Montigny challenged the leader of a trade group for compounding pharmacies that has lobbied to preserve state oversight of the industry, rather than accept some regulation by the US Food and Drug Administration.

Drug manufacturers are within the federal agency’s jurisdiction, but states have retained primary oversight of compounding pharmacies, including the Framingham one that produced tainted steroids blamed for sickening 620 people, including 39 who have died. Some critics of the compounding industry, which is supposed to custom-make drugs for individual patients, say states are not capable of fully monitoring what has become a complex and fast-growing field.